Clinical Trial Update: A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing [Phase 3]

View source ↗

Summary

This Phase 3 long-term safety study of albuterol delivered in a dry powder inhaler for asthma was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Albuterol (albuterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma | Phase 3 | Status: TERMINATED | Results posted: 2015-05-20